Drug
Vercirnon clinical trials
Includes 7 studies of Vercirnon.
- studies test it
- 11
- open now
- 0
- in phase 3
- 4
- first study started
- 2004
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
11 studies that test it; most in 2011 (4)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2010 | 3 |
| 2011 | 4 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 3
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Studies
Open first, then newest update. How each study uses vercirnon is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Phase II Study of CCX282-B in Patients With Celiac DiseaseCompletedPhase 2AmgenNCT00540657Written as CCX282-B
- Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's DiseaseCompletedPhase 2AmgenNCT00102921Written as CCX282-B
- A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's DiseaseCompletedPhase 2AmgenNCT00306215Written as CCX282-B
- An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's DiseaseTerminatedPhase 3GlaxoSmithKlineNCT01536418Written as GSK1605786A
- A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's DiseaseCompletedPhase 3GlaxoSmithKlineNCT01277666Written as GSK1605786A
- Open-Label Extension Study of GSK1605786ATerminatedPhase 3GlaxoSmithKlineNCT01318993Written as GSK1605786A
- GSK1605786A in the Maintenance of Remission in Subjects With Crohn's DiseaseTerminatedPhase 3GlaxoSmithKlineNCT01316939Written as GSK1605786A
- A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult SubjectsCompletedPhase 1GlaxoSmithKlineNCT01489943Written as GSK1605786 500 mg
- A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy SubjectsCompletedPhase 1GlaxoSmithKlineNCT01114607Written as GSK1605786 ChemoCentryx: formulation A
- Japanese Phase I of GSK1605786CompletedPhase 1GlaxoSmithKlineNCT01611805Written as GSK1605786
- Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese SubjectsCompletedPhase 1GlaxoSmithKlineNCT01827631Written as GSK1605786 capsule
Codes
What other systems call vercirnon · ClinicalTrials.gg INT017339
- UNII (FDA) MWI54OUA12VERCIRNONConfirmed FDA, Wikidata
- Wikidata Q27089138vercirnonConfirmed FDA, Wikidata
- NCI Thesaurus C152858VercirnonOne source FDA
- DrugBank DB15250One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | MWI54OUA12 | VERCIRNON | Confirmed FDA, Wikidata |
| Wikidata | Q27089138 | vercirnon | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152858 | Vercirnon | One source FDA |
| DrugBank | DB15250 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.